Search the Newsreel

VivoSim Labs regains Nasdaq compliance after cash infusion

VivoSim Labs (NASDAQ:VIVS) has regained compliance with Nasdaq listing rules after receiving a $5.0 million milestone payment from Eli Lilly, a $1.0 million release from escrow, and completing a $4.0 million financing round. These financial infusions, which occurred in July 2026, increased the company's …

Vivani Medical, Inc. (VANI) stock price, news, quote and history

Vivani Medical, Inc. (VANI) is a clinical-stage biopharmaceutical company focused on developing miniaturized subdermal drug implants for chronic diseases. The article provides a comprehensive overview of VANI's stock performance, including its current price, historical data, key financial metrics, and analyst ratings. It also details …

Delta Israel Brands (TASE:DLTI) Stock Rebounds With Profit Surge As Margins Lag

VivoSim regains Nasdaq compliance after $10.1 million cash update

VivoSim Labs (VIVS) has announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders’ equity of $2.5 million. This compliance was achieved through several events in July 2026, including a $5.0 million milestone payment from Eli Lilly, a …

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring a minimum stockholders’ equity of $2.5 million. This compliance was achieved through significant financial events in July 2026, including a $5.0 million milestone payment from Eli Lilly and Company, $1.0 …

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (VIVS) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a $5.0 million milestone payment and $1.0 million escrow release from Eli Lilly, along with $3.6 million net proceeds from a financing. The company reported $10.1 million cash on hand …

Semaglutide implant trial doses all 20 participants; data expected in November

Vivani Medical announced the successful dosing of all 20 participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management. The trial compares low-dose NPM-139 with Wegovy and focuses on safety, tolerability, pharmacokinetics, and weight change. …

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical announced the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The trial involves 20 GLP-1 naïve participants in Australia and aims to assess the safety, tolerability, and pharmacokinetics …

El Al Israel Airlines (TASE:ELAL) Stock Rebounds As Margin Pressure Persists

Price to earnings forward of VivoPower PLC Class A – TRADEGATE:51J

This page from TradingView provides financial information for VivoPower PLC Class A (TRADEGATE:51J), specifically focusing on its forward price-to-earnings ratio. The page indicates that the market was closed with no trades at the time of viewing. It appears to be a financial data portal, …

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

Vivos Therapeutics announced the issuance of a new US Patent (No. 12,697,190), broadening protection for its Vivos CARE oral medical device technology. This continuation patent, along with a previously issued patent, strengthens the intellectual property around their devices, which have received unprecedented FDA clearances …

Price to earnings forward of Naphtha Israel Petroleum Corp Ltd – TASE:NFTA

Innoviva earnings missed by $1.57, revenue topped estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) announced strong second-quarter 2026 financial results, driven by robust performance from its royalty portfolio and significant growth in Innoviva Specialty Therapeutics (IST) net product sales. The company achieved 19% year-on-year total revenue growth to $119.6 million and saw IST U.S. …

Innoviva (NASDAQ:INVA) Announces Quarterly Earnings Results, Misses Expectations By $1.58 EPS

Bezeq (TASE:BEZQ) Stock Faces A Margin Ceiling Despite Profit Progress

VivoSim Labs issues 9,896,718 shares on warrant exercises

VivoSim Labs issued 9,896,718 common shares between July 15 and July 31, 2026, due to the exercise of warrants. This issuance significantly increased the shares outstanding to 13,390,789 as of August 3, 2026, up from 3,194,295 on June 30, 2026. The warrant exercises followed …

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

Invivyd, Inc. (NASDAQ:IVVD) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $8.00. Institutional investors and hedge funds hold a significant 70.36% stake in the company, with some major firms increasing their positions. Despite this, Invivyd's shares opened …

Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology

Medical researcher pouring liquid into a beaker ©Adobe Stock Images The newly issued patent broadens intellectual property protection for Vivos' flagship oral medical device platform, reinforcing its competitive position in the obstructive sleep apnea treatment market. Key Investor Takeaways Vivos Therapeutics (NASDAQ:VVOS) received a …

Vivid Seats (SEAT) Stock Rebounds On World Cup Boosted EBITDA

Vivid Seats (SEAT) stock surged nearly 20% after reporting Q2 2026 earnings, driven by a World Cup boost that delivered $129.9 million in revenue and $12.6 million in adjusted EBITDA. While bulls see this as a sign of operating leverage and efficiency gains, bears …

Tel Aviv Stock Exchange (TASE:TASE) Stock P/E Premium Meets Record Margins

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) reported Q2 earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.56, and revenues of $119.59 million, also surpassing estimates by 5.63%. Despite outperforming estimates four times over the past year, the stock currently holds a Zacks Rank #5 (Strong …

Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $119.6M, vs. FactSet Est of $111.0M

Innoviva, Inc. reported its Q2 revenue of $119.6 million, surpassing the FactSet estimate of $111.0 million. The company, a diversified holding company with a focus on healthcare assets and royalties from respiratory products, also announced an update on its equity buyback plan. Innoviva's product …

Vivani Medical (VANI) to Announce Earnings on Wednesday

Vivani Medical (VANI) is set to release its Q2 2026 earnings before market open on Wednesday, August 12th, with analysts expecting a loss of $0.08 per share. The company previously matched consensus estimates with a similar loss in Q1. Insider transactions show Director Gregg …

Vivos sleep apnea devices gain broader protection after new patent

Vivos Therapeutics announced that the U.S. Patent and Trademark Office has issued a new patent, No. 12,697,190, which broadens protection for its Vivos CARE oral medical devices for sleep apnea treatment. This new patent is a continuation of a prior patent from 2024, providing …

Earnings call transcript: TASE posts record Q2 2026 results, shares rise 4.3%

Tel Aviv Stock Exchange posts surge in revenue and profit as market activity accelerates

Vivid Seats Inc. Q2 2026: Revenue $129.9M, Net loss $(14.3M) — 10-Q Summary

Vivid Seats Inc. reported its Q2 2026 financial results, with revenue reaching $129.9M and a net loss of $(14.3M), showing an improvement from the prior year's loss. The company experienced a decline in Marketplace and Private Label revenue but implemented cost-reduction programs and continued …

Invivyd (IVVD) Gains 7.27% to $0.61, Testing Key Resistance After Volatile Session - Cash Secured Put

What's Behind Viva Energy's (ASX:VEA) Share Price Move Today?

Trending Stocks Today | Vivos Therapeutics Soars 36.3% Post-Market

Vivos Therapeutics (VVOS) stock surged 36.3% in post-market trading today, reaching $1.54 after closing the regular session down 0.82% at $1.13. This significant jump follows recent positive momentum for the company.

Invivyd (IVVD) awards 1,125,000 stock options to CMO and Chief Epidemiologist

Invivyd, Inc. granted its Chief Medical Officer and Chief Epidemiologist, Michael Mina, 1,125,000 stock options with an exercise price of $0.535 per share, expiring on July 30, 2036. The options vest over four years, with 25% vesting on July 31, 2027, and the remainder …

Vivid Seats Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SEAT) 2026-08-04

VivoSim Labs Sets 2026 Annual Shareholder Meeting Date

VivoSim Labs (VIVS) announced that its 2026 Annual Meeting of Stockholders will take place on September 30, 2026, with August 13, 2026, designated as the record date. The meeting date was moved up by over 30 days compared to the previous year, necessitating an …

Invivyd grants 277,500 inducement stock options to new hires at $0.54 exercise price

Invivyd has granted 277,500 inducement stock options to 10 new non-executive employees under its 2026 Inducement Plan. The options have an exercise price of $0.54 per share, vesting over four years, with a 10-year term. This news brief was generated by Public Technologies (PUBT) …

TASE Reports the Results of the Financial Statements for the Second Quarter and the First Half of 2026